Kornimate/medical-research-clean huggingface dataset:
pharmaceutical care for chronic obstructive pulmonary disease (copd) study.

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: this study would like to test the hypothesis that a pharmaceutical care intervention would result in an improved drug adherence and inhalation technique in chronic obstructive pulmonary disease (copd) patients over a 3 month-period.

effective pharmacologic management of chronic obstructive pulmonary disease (copd) not only involves prescription of recommended medicines by the physician, but also implies correct use of the prescribed medication by the patient (ie, good drug adherence and correct inhalation technique). community pharmacists could help to improve the latter aspect, by delivering pharmaceutical care. the present randomised controlled trial will study the hypothesis that a pharmaceutical care intervention would result in an improved drug adherence and inhalation technique in copd patients over a 3 month-period.

Eligibility criteria:
inclusion criteria: * daily use of chronic obstructive pulmonary disease (copd)-medication: (global initiative for chronic obstructive lung disease: gold stadia i-iv) * 50 years of age or older * smoking history of at least 10 pack-years exclusion criteria: * having asthma * analphabetism

Keywords: chronic obstructive pulmonary disease copd
the paroxysmal nocturnal hemoglobinuria early access treatment protocol

Conditions: Hemoglobinuria, Paroxysmal

Summary: the primary objective is to provide access to eculizumab for pnh patient pending commercial availability.


Eligibility criteria:
inclusion criteria: * pnh; * at least 18 years old * avoid conception; and * willing and able to give written informed consent exclusion criteria: * active bacterial infection * participation in any other drug trial * pregnant breast feeding, or intending to conceive * not vaccinated against n meningitidis
effects of lacticaseibacillus rhamnosus lra05 on bacterial vaginosis and ovarian function in women

Conditions: Patients With Bacterial Vaginosis

Summary: in this study, lacticaseibacillus rhamnosus lra05 was selected as test preparations to observe the clinical efficacy in the intervention trial of combined antibiotic therapy, and to evaluate its effects on the cure rate, recurrence rate and vaginal microbiota of patients with bacterial vaginitis.


Eligibility criteria:
inclusion criteria: 1. 18 to 65 years old, sexual activity, premenopausal women; 2. nugent score for diagnosing bv ≥7; 3. signed informed consent. exclusion criteria: 1. mixed vaginitis, such as vulvovaginal candidiasis (vvc), trichomonas vaginalis (tv) infection, chlamydia trachomatis (ct) infection or gonococcal vaginitis; 2. history of systemic organic disease or psychiatric illness; 3. planning pregnancy, breastfeeding, menstruation; 4. within 5 days of the onset of the disease, any antibiotics have been used; 5. long-term use of contraceptives or immunosuppressants; 6. allergic constitution or hypersensitivity to known components of the study drug.
myocardial protection and anesthetic agents

Conditions: Myocardial Ischemic Reperfusion Injury

Summary: the aim of this study was to investigate the myocardial protective effects of remifentanil and dexmedetomidine in cardiac surgery.

fifty patients is included in this study. routine monitorization included a 5-lead electrocardiogram (ecg), invasive arterial monitoring, pulse oximetry, capnography, temperature monitoring. invasive arterial catheter were inserted under local anesthesia. central venous catheter (jugular or subclavian) and esophageal heat probe were inserted after tracheal intubation. anesthesia induction was standardized in all patients and included 1 mg/kg propofol, 1 μg/kg fentanyl and 0.1 mg/kg vecuronium bromus to facilitate endotracheal intubation. the patients were divided into two groups by computer randomization method. group r (n=25), remifentanil group and group d (n=25) dexmedetomidine group. in the remifentanil group, anesthesia was maintained with 0.5-1.5% sevoflurane and 0.125-0.25 μg/kg/min remifentanil infusion. in the dexmedetomidine group anesthesia was maintained with 0.5-1.5% sevoflurane and 0.5 μg/kg dexmedetomidine loading dose during 10 minute and 0.3-0.9 μg/kg/min infusion. cardiopulmonary bypass (cpb) period was started after aort and venous cannulae were inserted. mean arterial pressure, central venous pressure, venous oxygen saturation (svo2) and arterial blood gase analysis were recorded. all blood samples include laktat, pyruvate, ckmb and troponin-t were taken via the coronary sinus catheter at specific time intervals (precardiopulmonary bypass, 20 minutes after cross clamp, 20 minutes after removal cross clamp and 10 minutes after cardiopulmonary bypass). cardiopulmonary bypass time, aortic cross clamping time, the need of defibrillation/intraaortic balloon pumping (iabp)/extracorporeal membrane oxygenator (ecmo), urine output, positive inotropic agents requirement were recorded. at the end of surgery, the patients were transferred intensive care unit intubated and full monitorized.

Eligibility criteria:
inclusion criteria: * scheduled to open heart surgery * american society of anesthesiologists (asa) physical status of ii-iii exclusion criteria: * emergency surgery, prior cardiac surgery, ejection fraction \< 50%, restrictive or obstructive pulmonary disease, preoperative mechanical ventilation, intra-aortic balloon pump, chronic liver and renal failure.
a study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of tripegfilgrastim in pediatric solid tumor/lymphoma patients

Conditions: Solid Tumor; Lymphoma

Summary: this is an open-label, single ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of tripegfilgrastim in pediatric solid tumor/lymphoma patients


Eligibility criteria:
inclusion criteria: * \>=6 and \<19-year-old pediatrics with solid tumor/lymphoma * scheduled for chemotherapy requiring g-csf support or having given an experience of anc \< 0.5x10\^9/l * anc \> 0.75x10\^9/l, platelet \> 75x10\^9/l * ecog performance status 0 or 1 exclusion criteria: * patients with leukemia, myelodysplastic syndrome or uncontrolled infectious/nervous diseases * history of allergy to filgrastim, pegfilgrastim or known hypersensitivity to e-coli derived proteins. * women who are pregnant or lactating
ultrasound-guided tibial nerve block vs. local corticosteroid injection in recalcitrant plantar fasciitis treatment

Conditions: Plantar Fascitis; Tibial Nerve; Injections; Ultrasonography

Summary: a randomized controlled study to search for the efficiency of tibial nerve block vs local corticosteroid injection of the plantar fascia.

three groups will be formed. after eswt therapy, if the patients still suffer from pain (\> 5 points, visual analog scale(0-10points), participants will be included in the study. one group will receive conversational therapy. second group will be treated with local corticosteroid injection. and third group will be treated with tibial nerve block. before-treatment, after one week, after six weeks and after 3 months evaluation of the patients will be performed.

Eligibility criteria:
inclusion criteria: * recalcitrant plantar fasciitis exclusion criteria: -

Keywords: plantar fascitis tibial nerve injections ultrasonography
influence of oral treatment with citicoline for the prevention of radiation optic neuropathy in patients treated for uveal melanomas with proton beam therapy

Conditions: Uveal Melanoma

Summary: proton beam irradiation is the treatment of choice for uveal melanomas. it has favorable results in causing tumor regression while preserving the eye. optic neuropathy has emerged consistently as an irreversible cause of visual loss in proton beam irradiated eyes. no neuroprotective strategies are available at present. citicoline is a choline agent precursor available as a dietary supplement. citicoline conferred acute neuroprotection and enhanced neuroplasticity in experimental stroke models. in ophthalmology, citicoline has demonstrated a significant action in improving retinal and cortical responses in patients with optic nerve diseases (glaucoma, ischemic optic neuropathy). citicoline also exhibits a very low toxicity profile in humans. the purpose of the study is to demonstrate whether daily oral administration of citicoline in patients treated for uveal melanomas with proton beam therapy, prevents or delays the occurrence of radiation optic neuropathy. changes in visual acuity, pattern erg and visual evoked potentials are measured. the tolerability/safety of the product is also evaluated.


Eligibility criteria:
inclusion criteria: * over 18 years old * uveal melanoma with posterior marge located at less than 3 mm of optic papilla * uveal melanoma treated with proton beam therapy with irradiation of optic head nerve * visual acuity before proton beam therapy over 30 letters (with etdrs test) exclusion criteria: * antecedent of acute glaucoma with angle enclosure * antecedent of chronical glaucoma with angle aperture * antecedent of optic neuropathy optique of congenital, ischemic, inflammatory or other origins * antecedent of neovascular glaucoma
prevalence of hyperventilation syndrome in difficult asthma

Conditions: Difficult Asthma; Severe Persistent Asthma; Hyperventilation Syndrome

Summary: most of asthmatics patients remain uncontrolled despite an inhaled steroids treatment. chronic hyperventilation syndrome (also called idiopathic hyperventilation) occurs in 20 to 40% of asthmatic patients. the purpose of the study is to assess the prevalence of chronic hyperventilation syndrome in a specific population of difficult-to-treat asthmatics patients, those who receive daily high doses of inhaled steroids (≥ 1000 µg of fluticasone with an additional treatment by a long-acting beta 2-agonist (laba) and who remain uncontrolled (asthma control test (act) \< 18). we plan to realize a systematic assessment of the diagnosis of chronic hyperventilation syndrome with the nijmegen questionnaire, blood gases at rest, hyperventilation testing and cardiopulmonary exercise testing(cpet). we also will collect demographic information as well as information about asthma history, asthma control and treatment.

there is only one visit. during this visit, each patient will complete self-questionnaires like nijmegen, hospital anxiety and depression scale(had), short-form 36(sf36), and asthma quality of life questionnaire (aqlq), the participants will have baseline spirometry and fractional exhaled nitric oxide measured at expiratory flow of 50 ml/s (feno50), blood gases at rest, an hyperventilation challenge and cardiopulmonary exercise testing(cpet) to determine accurately the presence or not of chronic hyperventilation syndrome. the diagnosis is confirmed by two positive tests (nijmegen, hyperventilation challenge and blood gases) and the final decision of a medical committee. the first step is to determine the prevalence oh this syndrome in this specific population. the second step is to assess the sensitivity, the specificity, the false positive rate and the false negative rate of the different parameters measured during the tests.

Eligibility criteria:
inclusion criteria: * men and women, * aged more than 18, * non smokers for two years or longer, less than 10 pack/years smoking history, * physician-diagnosed asthma, * uncontrolled asthma with asthma control test (act) \< 18, * historical of fev1 reversibility, * daily inhaled steroids treatment by at least 2000microg eq beclomethasone, * forced expiratory volume in 1 second (fev1) \> 50% predicted value exclusion criteria: * other chronic pulmonary disease, * vocal cord dysfunction, * pregnancy, * participation in another interventional research trial, * unable to provide consent, * asthma exacerbation within the last 4 weeks

Keywords: difficult asthma hyperventilation syndrome prevalence
effects of tirzepatide on blood, imaging and breast tissue biomarkers

Conditions: Obesity; Breast Cancer Risk

Summary: evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.

women who are scheduled to take tirzepatide for weight loss will be assessed before and after taking drug for change in risk biomarkers. these include mammography, dxa scan, blood draw, and random periareolar fine needle aspiration (rpfna) for acquisition of benign breast tissue.

Eligibility criteria:
inclusion criteria: * • bmi 30-45 kg/m2 * female * insurance approved or likely approved for tirzepatide clinical use \* * additional risk factors for breast cancer other than obesity (any one or more) first or second degree with breast cancer known high density on mammogram (heterogenous or extremely dense) prior biopsy showing atypical hyperplasia or lcis prior treated dcis known carrier breast cancer predisposition gene mutation or known mutation in family member . 2- fold or higher estimated 10 year or lifetime risk compared to population by standard risk model (bcrat, bcsc, ibis exclusion criteria: * • subglandular breast implants (women with subpectoral implants are eligible if c cup or greater; breast can easily be pulled off the chest wall; and with approval of pi) * clinical contra-indication to incretin mimetics * insurance/third party has denied coverage and participant does not wish to do self-pay. * child-bearing potential and not on contraceptives * prior invasive breast cancer * currently taking any of the following medications: insulin, tamoxifen, raloxifene, letrozole, arimidex, exemestane, incretin mimetics.
effect of early feeding of breast milk

Conditions: Neonatal SEPSIS; Weight Gain; Feeding Disorder Neonatal

Summary: breast milk is an extremely complex and highly variable biofliud that has evolved to nourish infants and protect them from disease whilst their own immune system matures. the composition of human breast milk changes in response to many factors, matching the infants requirement according to its age and other characteristics.

breast milk is an extremely complex and highly variable biofliud that has evolved to nourish infants and protect them from disease whilst their own immune system matures. the composition of human breast milk changes in response to many factors, matching the infants requirement according to its age and other characteristics. therefore, the composition of breast milk is widely believed to be specifically tailored by each mother to precisely reflect the requirements of her infant. human milk is uniquely suited to the human infant, both in its nutritional composition and in the non-nutritive bioactive factors that promote survival and healthy development. breast milk contains over 400 different proteins which perform a variety of functions; providing nutrition, possessing antimicrobial and immunomodulatory activities, as well as stimulating the absorption of nutrients. the immune system of preterm infants is immature, placing them at increased risk for serious immune-related complications. human milk provides a variety of immune protective and immune maturation factors that are beneficial to the preterm infants poorly developed immune system. the most studied immune components in human milk include antimicrobial proteins, maternal leukocytes, immunoglobulins, cytokines and chemokines, oligosaccharides, gangliosides, nucleotides, and long-chain polyunsaturated fatty acids. there is growing evidence that these components contribute to the lower incidence of immune-related conditions in the preterm infant. therefore, provision of these components in human milk, donor milk, or formula may provide immunologic benefits. the effects of breast milk and breastfeeding on neurodevelopment may be quite different in very preterm infants than in those born at full term. nutritionally, breast milk is considered the optimal food for full term infants. but preterm infants require fortification to match third trimester nutrient accretion rates.

Eligibility criteria:
inclusion criteria: 1. gestational age \<37 weeks. 2. birth weight \>1000 gm. exclusion criteria: 1. gestational age 37 weeks. 2. birth weight \< 1000 gm. 3. newborns with congenital anomalies. 4. newborns with suspected metabolic diseases. 5. newborns on mechanical ventilators. 6. newborns with suspected neonatal sepsis.
monitor the incidence of congenital malformations in infants of women who have been treated with ganirelix (orgalutran®)(study 38644)(p05966)(completed)

Conditions: Pregnancy; Neonates

Summary: the primary purpose of this study is to collect data on the incidence of congenital malformations in infants of women with an ongoing pregnancy after controlled ovarian stimulation with recombinant follicle stimulating hormone /ganirelix followed by in vitro fertilization (ivf) or intra cytoplasmatic sperm injection (icsi), and to compare this incidence with that of a group of women who used a long protocol with a gonadotropin releasing hormone agonist as historical controls.


Eligibility criteria:
inclusion criteria: * puregon® (recfsh)/orgalutran® group: * women with a pregnancy of \>= 16 weeks after puregon® /orgalutran® treatment for ivf or icsi and et of fresh embryos. treatment is defined as having had at least one injection of orgalutran®. * women between 18 and 39 years of age (inclusive) at the day of hcg. * women who are able and willing to sign informed consent. controls * infants (gestational age \>=16 weeks) of women pregnant after coh using a gnrh agonist in a long protocol for ivf or icsi and et of fresh embryos. * infants of women between 18 and 39 years of age (inclusive) at the day of hcg. * the most recent 1000 infants delivered prior to january 1, 2001. exclusion criteria: * none

Keywords: neonatal outcome congenital malformations in-vitro fertilization controlled ovarian stimulation follow-up
cd70-targeted immunopet imaging of kidney cancer

Conditions: Urologic Neoplasms; Urogenital Neoplasms; Kidney Neoplasms; Neoplasms

Summary: the aim of this study is to establish and optimize the \[18f\]rccb6 pet/ct imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.

histologically confirmed diagnosis of kidney cancer (especially clear cell renal cell carcinoma and papillary renal cell carcinoma) or suspected kidney cancer by diagnostic imaging will be included. especially patients with suspected metastases or routine follow-up or surveillance or suitable for systemic treatments (e.g., combined immunotherapy and targeted therapies) will undergo \[18f\]rccb6 immunopet/ct scans. for clear cell renal cell carcinoma patients receiving systemic treatments, repeated cd70-targeted immunopet imaging might be performed. enrolled patients will undergo whole-body \[18f\]rccb6 immunopet/ct scans at 1-2 hours after tracer injection(0.05-0.1 mci/kg). uptake of \[18f\]rccb6 in tumor and normal organs/tissues will be scored visually and quantitatively. tumor uptake will be quantified by the maximum standard uptake value (suvmax). the sensitivity, specificity, positive predictive value (ppv), negative predictive value (npv), and accuracy will be calculated to evaluate the diagnostic efficacy. the correlation between lesion uptake and protein expression level determined by immunohistochemistry staining will be further analyzed. the exploration endpoint will be the imaging feasibility and preliminary diagnostic value of the above tracer.

Eligibility criteria:
inclusion criteria: 1. aged 18-80 year-old and of either sex； 2. histologically confirmed diagnosis of kidney cancer (especially clear cell renal cell carcinoma and papillary renal cell carcinoma) or suspected kidney cancer by diagnostic imaging; 3. capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (icf) and this protocol. exclusion criteria: 1. pregnancy； 2. severe hepatic and renal insufficiency; 3. history of serious surgery in the last month; 4. allergic to antibody or single-domain antibody radiopharmaceuticals.

Keywords: the cluster of differentiation (cd70) kidney tumor clear cell renal cell carcinoma immunopet
incidence of infective endocarditis in end stage renal disease patients on hemodialysis by transesophageal echocardiography in assuit university hospital

Conditions: Infective Endocarditis; End Stage Renal Disease

Summary: 1. to detect in more detail the incidence of infective endocarditis in patients with end stage renal disease (esrd) on hemodialysis. 2. to compare the relationship between different forms of haemodialysis access type and the related incidence of infective endocarditis. 3. to determine individual risk factors, including type of vascular haemodialysis access, previous valve lesion and immunocompromised patients.

all patients will undergo tte and tee within 36 hours of symptoms. tte will be performed with a 2.5- or 3.5-mhz phased-array transducer. patients will fast for more than 4 hours before tee, which will be performed under local pharyngeal anesthesia; the majority of patients will also receive intravenous midazolam (0.5 to 2.0 mg). a 5-mhz phased-array transducer (either biplane or multiplane) will be used for the transesophageal examination, which consisted principally of two-dimensional imaging and color flow mapping and will be performed without any complications in all patients. all echocardiograms will be evaluated later during reading sessions by two observers. tte studies will be defined as technically inadequate if both observers deemed the quality of the images to be insufficient to gain diagnostic information regarding the presence or absence of vegetations or their complications. findings on tte and tee will be separately categorized as indicating high, intermediate, or low probability for endocarditis as follows: high, any definite vegetation and/or abscess or probable vegetation with evidence of otherwise unexplained valvular dysfunction (greater than mild regurgitation or a paravalvular prosthetic leak); intermediate, a probable vegetation without evidence of unexplained valvular dysfunction; and low, no evidence of vegetation or abscess or a possible vegetation without any evidence of regurgitation. 3 sets of blood culture with one hour interval will be withdrawn from the central line from all patients, before stating antibiotics within 24 hours from the onset of symptoms.

Eligibility criteria:
inclusion criteria: * incidence of infective endocarditis in esrd that on hemodialysis. * must be fit for transoesophageal echo. exclusion criteria: * any patient with sepsis due to causes other than infected vascular access.
covid-19 antibodies among healthcare workers

Conditions: COVID-19; SARS-CoV 2

Summary: observational, point of prevalence study determining the presence of anti-sars-cov-2 antibody

all healthcare workers (hcw) who had entered contaminated areas at least once and that 14 days or more had passed from their first entrance to contaminated areas were included. they were classified as asymptomatic and pauci-symptomatic. a covid-19 igg/igm rapid test was used for antibody detection, and selected participants were subject to real time polymerase chain reaction (qpcr) for sars-cov-2.

Eligibility criteria:
inclusion criteria: * all healthcare workers who had entered contaminated areas at least once and that 14 days or more had passed from their first entrance were included exclusion criteria: * healthcare workers who did not have exposure for more or equal 14 days * healthcare workers who did not wish to participate